A novel TNFR1 targeting domain antibody attenuates pulmonary inflammation in a human model of lung injury, via actions on the lung micro vascular endothelium

Alastair G Proudfoot,Cecilia M O'Kane,Andrew Bayliffe,Adrian P Serone,Philippe Bareille, Stephen P Smith,Vanessa Brown,Tracey J Wright,Younan Chen,Rob Wilson, Joanna C Cordy,Peter J Morley,Stuart Elborn,Matthew Hind,Edwin R Chilvers,Mark J Griffiths,Charlotte Summers,Danny F McAuley

A47. Critical Illness: Novel Molecules and Models（2014）

引用 6|浏览9

暂无评分

摘要

Methods:In a double-blinded placebo controlled study healthy subjects were randomised to nebulised GSK1995057 or placebo (1: 1), administered 1 hour prior to LPS inhalation. Bronchoalveolar lavage fluid (BALF) was collected 6 hours after LPS challenge. Parallel experiments in vitro were undertaken to determine the effects of GSK1995057 on the permeability, ligand expression and cytokine production of human pulmonary micro-vascular endothelial cells (HMVEC-L)Results:

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要